14 results on '"Claudia Fabrizio"'
Search Results
2. Variability OF HIV-1 V2 env domain for integrin binding: Clinical correlates
- Author
-
Claudia Fabrizio, Flavia Balena, Antonella Lagioia, Luciana Lepore, Davide Fiore Bavaro, Annalisa Saracino, Gioacchino Angarano, Laura Monno, and Luigia Scudeller
- Subjects
Integrins ,Glycosylation ,Amino Acid Motifs ,Integrin ,Human immunodeficiency virus (HIV) ,HIV Infections ,Tripeptide ,HIV Envelope Protein gp120 ,Biology ,medicine.disease_cause ,α4β7 integrin ,03 medical and health sciences ,chemistry.chemical_compound ,Virology ,medicine ,Humans ,Clinical significance ,030304 developmental biology ,Integrin binding ,0303 health sciences ,Binding Sites ,Polymorphism, Genetic ,Host Microbial Interactions ,030302 biochemistry & molecular biology ,Sequence Analysis, DNA ,chemistry ,HIV-1 ,biology.protein ,Protein Binding ,Homing (hematopoietic) - Abstract
The HIV V2179-181 (HXB2 numbering) tripeptide mediates binding to α4β7 integrin, which is responsible for GALT homing. Our study aimed to assess V2 variability in naive HIV-1 infected patients and its association with clinical and viro-immunological features. Gp120 sequences were obtained from 322 subjects; length, potential N-linked glycosylation sites (PNGs), net-charge (NC) and 179-181tripeptide α4β7-binding-motif of V2 were evaluated. At multivariate analysis, lower V2 length and higher NC correlated with low CD4 cells; no association was found with PNGs. A greater variability pertained positions 162-163, 164-167, 169, 175-179, 187, 194 and 195 in B sequences, and 163 and 177 in X4 tropic viruses. LDV was the most common tripeptide. Asp180 was highly conserved; Leu179 was more frequently observed in non-B and in recent infections compared to others, while Val181 was found in recent infections and in MSM. Further studies to deeply explore the clinical significance of these associations are warranted.
- Published
- 2019
3. Short-term outcomes in individuals aged 75 or older with severe coronavirus disease (COVID-19): First observations from an infectious diseases unit in Southern Italy
- Author
-
Giuseppe Bruno, Serena Perelli, Giovanni Buccoliero, and Claudia Fabrizio
- Subjects
Microbiology (medical) ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,Pneumonia, Viral ,Disease ,medicine.disease_cause ,Article ,Betacoronavirus ,Risk Factors ,Pandemic ,Medicine ,Humans ,Pandemics ,Coronavirus ,Aged ,biology ,business.industry ,SARS-CoV-2 ,COVID-19 ,biology.organism_classification ,Virology ,Infectious Diseases ,Italy ,business ,Coronavirus Infections - Abstract
Highlights • In elderly COVID-19 inpatients, admission NEWS2 scores did not predict mortality. • Of components of NEW2 score, only systolic blood pressure predicted mortality. • A high variability in NEW2 score predicted mortality. • NEWS2 score does not consider the degree of supplemental oxygen patients require. • A more sensitive early warning score for COVID-19 is needed.
- Published
- 2020
- Full Text
- View/download PDF
4. Pancreatic injury in the course of coronavirus disease 2019: A not‐so‐rare occurrence
- Author
-
Giuseppe Bruno, Claudia Fabrizio, Carmen Rita Santoro, and Giovanni Buccoliero
- Subjects
2019-20 coronavirus outbreak ,medicine.medical_specialty ,Coronavirus disease 2019 (COVID-19) ,business.industry ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,medicine.disease ,Virology ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,Infectious Diseases ,Internal medicine ,medicine ,Inflammatory cascade ,030211 gastroenterology & hepatology ,030212 general & internal medicine ,Pancreatic injury ,Respiratory system ,business - Abstract
Despite respiratory symptoms are typically found during the course of coronavirus disease 2019 (COVID‐19), gastrointestinal manifestations are increasingly described. However, data regarding COVID‐19‐associated pancreatic injury are still limited, as well as the mechanisms underlying COVID‐19 induced‐pancreatic damage have not been completely clarified. Herein, we described pancreatic abnormalities in six (8.5%) out of 70 patients with COVID‐19 hospitalized in our unit from February 25, 2020 to May 10, 2020. We hypothesized that pancreatic damage may be associated with several factors including direct effect of SARS‐CoV‐2, inflammatory cascade, dehydration and multiple organ dysfunction.This article is protected by copyright. All rights reserved.
- Published
- 2020
- Full Text
- View/download PDF
5. Gp120 substitutions at positions associated with resistance to fostemsavir in treatment-naive HIV-1-positive individuals
- Author
-
Claudia Fabrizio, Gioacchino Angarano, Antonella Lagioia, Annalisa Saracino, Laura Monno, Luciana Lepore, Davide Fiore Bavaro, Anna Volpe, and Eugenio Milano
- Subjects
0301 basic medicine ,Microbiology (medical) ,030106 microbiology ,Population ,Human immunodeficiency virus (HIV) ,HIV Infections ,Biology ,HIV Envelope Protein gp120 ,medicine.disease_cause ,Virus ,Piperazines ,Therapy naive ,03 medical and health sciences ,0302 clinical medicine ,Post-hoc analysis ,medicine ,Humans ,Pharmacology (medical) ,030212 general & internal medicine ,education ,Tropism ,Retrospective Studies ,Pharmacology ,chemistry.chemical_classification ,education.field_of_study ,Virology ,Organophosphates ,Amino acid ,Infectious Diseases ,Fostemsavir ,chemistry ,HIV-1 - Abstract
Objectives Fostemsavir, a novel attachment inhibitor targeting the HIV-1 gp120, has demonstrated wide in vitro activity. However, the high rate of HIV gp120 substitutions could jeopardize its efficacy. We investigated envelope (env) substitutions at positions associated with resistance to fostemsavir in patients with a new HIV-1 diagnosis according to HIV subtype and tropism. Methods Gp120 sequences from 409 subjects were retrospectively analysed and the presence of the L116P, A204D, S375H/M/T, M426L, M434I and M475I mutations was evaluated. Other amino acid changes at the same positions were also recorded. The variability at each amino acid position was evaluated using Shannon entropy. Results The frequency of mutations was: S375T (13.2%); M426L (6.8%); M434I (2.9%); M475I (2.7%); S375H (1.0%)/M (0.8%) and L116P (0.31%). Statistically significant differences were found at positions 375 (R5/non-R5 strains and B/non-B subtypes) and 426 (B/non-B subtypes); post hoc analysis revealed that significance for position 375 was steered by S375T while for position 426 significance was governed by unusual substitutions, in particular M426R (B/non-B, P Conclusions In conclusion, gp120 substitutions were detected in different subtypes and in both R5 and non-R5 variants. Despite the great variability of gp120, the frequency of mutations was low overall and the predominant substitution was S375T, the role of which in reducing fostemsavir efficacy is less substantial.
- Published
- 2019
6. HCV mono-infected and HIV/HCV co-infected individuals treated with direct-acting antivirals: to what extent do they differ?
- Author
-
Annalisa Saracino, Gioacchino Angarano, Claudia Fabrizio, Michele Milella, Nicoletta Ladisa, Luigia Scudeller, Giuseppe Bruno, Eugenio Milano, Laura Monno, and Raffaele Dell’Acqua
- Subjects
Microbiology (medical) ,Liver Cirrhosis ,Male ,medicine.medical_specialty ,Cirrhosis ,SVR ,Genotype ,Hepatitis C virus ,HIV Infections ,Hepacivirus ,medicine.disease_cause ,Direct-acting antivirals ,Gastroenterology ,Antiviral Agents ,HIV/HCV co-infection ,law.invention ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,Liver disease ,0302 clinical medicine ,Randomized controlled trial ,law ,Internal medicine ,Medicine ,Humans ,lcsh:RC109-216 ,030212 general & internal medicine ,Adverse effect ,business.industry ,Coinfection ,virus diseases ,DAAs ,Real world ,General Medicine ,Odds ratio ,Middle Aged ,medicine.disease ,Virology ,Hepatitis C ,Discontinuation ,Infectious Diseases ,Treatment Outcome ,Tolerability ,030211 gastroenterology & hepatology ,Female ,Safety ,business - Abstract
Background Direct-acting antiviral (DAA)-based treatment of hepatitis C virus (HCV) has been associated with high sustained virological response (SVR) rates and good tolerability in randomized clinical trials. This study was performed to assess the safety and effectiveness of DAAs in both HCV mono-infected and HIV/HCV co-infected patients. Methods All consecutive HCV-infected patients, including HIV/HCV co-infected patients, receiving DAA-based treatment from February 2015 to September 2016 at the study clinic were included. Clinical, virological, and biochemical data were retrieved. The primary end-point was the SVR12 (HCV RNA undetectable 12 weeks after the end of treatment) is commonly used worldwide. The secondary end-point was the safety profile of DAAs during the treatment period. Results A total of 382 patients were included; 62 were HIV/HCV co-infected. Cirrhosis was found in 256 patients (67.4%). SVR12 was achieved in 365/382 (95.5%) individuals (58/62 HIV/HCV co-infected, 93.5%) in the intention-to-treat (ITT) analysis. A platelet count 9 /l (odds ratio (OR) 4.12, 95% confidence interval (CI) 1.5–11.3, p =0.006), HCV genotype 3 infection (OR 5.49, 95% CI 1.9–15.7, p =0.002), liver stiffness >20kPa (OR 3.05, 95% CI 1.03–8.96, p =0.04), and Model for End-Stage Liver Disease (MELD) score >10 (OR 5.27, 95% CI 1.16–23.8, p =0.03) were associated with lower SVR rates. On multivariate analysis, only genotype 3 infection remained a negative predictor of SVR (OR 21.6, 95% CI 3.81–123, p =0.001). Treatment discontinuation was observed in 10 subjects. Severe adverse events (SAEs) occurred in 17 patients (4.5%). Conclusions High SVR12 rates were observed in both HCV mono-infected and HIV/HCV co-infected individuals. Overall, DAA-based treatment was safe and there were no differences in terms of SAEs and treatment discontinuation between the two groups.
- Published
- 2017
7. HIV-1 coreceptor tropism: A syllogistic connection with The Veterans Aging Cohort Study Index and the CD4/CD8 ratio
- Author
-
Annalisa Saracino, Antonella Lagioia, Nicolò De Gennaro, Armando Leone, Claudia Fabrizio, Grazia Punzi, Luciana Lepore, Laura Monno, Luigia Scudeller, and Gioacchino Angarano
- Subjects
0301 basic medicine ,Male ,RNA viruses ,Human immunodeficiency virus (HIV) ,CD4-CD8 Ratio ,HIV Infections ,medicine.disease_cause ,Pathology and Laboratory Medicine ,Cohort Studies ,0302 clinical medicine ,Immunodeficiency Viruses ,Risk Factors ,Antiretroviral Therapy, Highly Active ,030212 general & internal medicine ,Veterans ,Multidisciplinary ,HIV diagnosis and management ,Middle Aged ,Italy ,Medical Microbiology ,Viral Pathogens ,Viruses ,Cardiology ,Infectious diseases ,Medicine ,Female ,Pathogens ,Coreceptors ,Cohort study ,Research Article ,Signal Transduction ,Cart ,Adult ,medicine.medical_specialty ,Receptors, CXCR4 ,Receptors, CCR5 ,Science ,Men WHO Have Sex with Men ,Viral diseases ,Microbiology ,03 medical and health sciences ,Internal medicine ,Virology ,Retroviruses ,medicine ,Humans ,Microbial Pathogens ,Medicine and health sciences ,business.industry ,Lentivirus ,Organisms ,Genetic Variation ,Biology and Life Sciences ,HIV ,CD coreceptors ,Cell Biology ,030112 virology ,Antiretroviral therapy ,Diagnostic medicine ,CD4 Lymphocyte Count ,Regimen ,Viral Tropism ,Increased risk ,People and Places ,Coreceptor tropism ,HIV-1 ,Population Groupings ,business ,Sexuality Groupings - Abstract
Background The association between X4 virus and an increased risk of non-AIDS-events has been reported. Morbidity/mortality due to non-AIDS events, which are properly predicted by the CD4/CD8 ratio and VACS index, have become particularly remarkable in HIV-infected patients receiving effective combined antiretroviral therapy (cART). Methods We verified the validity of the syllogism: as HIV-tropism (CRT) contributes to the onset of non-AIDS events which are successfully predicted by the CD4/CD8 ratio and VACS index, then CRT correlates with these two variables. The CD4/CD8 ratio and VACS index at baseline and overtime were analyzed according to CRT tested before the first successful cART regimen in newly-diagnosed patients. Results Patients with R5 variants had a significantly lower baseline VACS percentage risk [mean (95%CI):18.2%(16.1-20.3) vs 24.3%(18.2-22.5), p = 0.002] and higher baseline CD4/CD8 ratio [mean (95%CI):0.43 (0.38-0.47) vs 0.28 (0.19-0.36), p = 0.002] than non-R5 patients. After an initial drop, VACS increased again in R5 and non-R5 patients and the two trend curves almost overlapped. The CD4/CD8 ratio had an increasing trend in both R5 and non-R5 patients; however, even though non-R5 patients had a greater gain of CD4+, they maintained a lower CD4/CD8 ratio at any time point. Conclusion Our study confirms an association between pre-therapy CRT, CD4/CD8 ratio and VACS. A successful cART regimen positively affects the CD4/CD8 ratio; however, the disadvantage conferred by a non-R5 CRT is maintained overtime. The restoration of VACS in all patients could be directly due to variables included in the VACS calculation and to factors that adversely influence these variables.
- Published
- 2019
8. COVID-19-associated pulmonary aspergillosis: adding insult to injury
- Author
-
Claudia Fabrizio, Giovanni Buccoliero, and Giuseppe Bruno
- Subjects
Microbiology (medical) ,lcsh:R5-920 ,2019-20 coronavirus outbreak ,Coronavirus disease 2019 (COVID-19) ,business.industry ,media_common.quotation_subject ,Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ,lcsh:QR1-502 ,Microbiology ,Article ,lcsh:Microbiology ,Insult ,Pulmonary aspergillosis ,Infectious Diseases ,Virology ,Immunology ,Medicine ,lcsh:Medicine (General) ,business ,media_common - Published
- 2020
9. HIV-RNA decay in paired blood and semen samples of subjects receiving their first dolutegravir-based ART regimen
- Author
-
Nicoletta Ladisa, Annalisa Saracino, Anna Volpe, Gioacchino Angarano, Luigia Scudeller, Katia Falasca, Laura Monno, Antonella Lagioia, Claudia Fabrizio, and Nicolò De Gennaro
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Sexual transmission ,Adolescent ,Anti-HIV Agents ,Pyridones ,Art initiation ,Semen ,HIV Infections ,Piperazines ,03 medical and health sciences ,chemistry.chemical_compound ,Young Adult ,0302 clinical medicine ,Virology ,Internal medicine ,Antiretroviral Therapy, Highly Active ,Oxazines ,medicine ,Humans ,030212 general & internal medicine ,Viral suppression ,HIV Integrase Inhibitors ,Prospective Studies ,business.industry ,Middle Aged ,Viral Load ,Antiretroviral therapy ,Regimen ,030104 developmental biology ,Infectious Diseases ,chemistry ,Dolutegravir ,HIV-1 ,RNA, Viral ,Observational study ,business ,Heterocyclic Compounds, 3-Ring - Abstract
We aimed to investigate to what extent a first-line DTG-based ART regimen reduces HIV-RNA in semen compared to plasma.In this prospective, observational study, ART-naïve, HIV-infected males starting their first ART regimen with DTG plus TDF/FTC or ABC/3TC were enrolled. Paired blood (BP) and seminal plasma (SP) samples were collected at baseline (T0) and at week-2/4/12/24 after ART initiation. Sexually transmitted infections (STI) were ruled out before enrolment.Median baseline HIV-RNA levels were lower in SP compared to BP (657 versus 38.200 copies/ml, p 0.001), three subjects had undetectable semen HIV-RNA. After 12 weeks of treatment, HIV-RNA was below the quantification limit in both BP and SP of 11 pts (61.1%). Discordant results were obtained in 6 subjects (33.3%), showing quantifiable HIV-RNA in blood only (2 cases) and in semen only (4 cases). Finally, one subject had a positive HIV-RNA in SP/BP. At W24, only in 2/16 subjects (12.5%) HIV-RNA was detectable in semen, while in the others it was negative on SP/BP. No concurrent STI was found in subjects with detectable VL in semen.DTG demonstrated effectiveness in reducing VL with different kinetics in blood and semen, despite seminal viral suppression after 6 months of ART was not obtained in the totality of subjects.
- Published
- 2018
10. An intricate case of multidrug resistant Plasmodium falciparum isolate imported from Cambodia
- Author
-
Claudia Fabrizio, Laura Monno, Raffaele Dell’Acqua, Gioacchino Angarano, Annalisa Saracino, Francesco Castelli, Mariangela L’Episcopia, Francesco Di Gennaro, Sergio Lo Caputo, Michela Menegon, and Carlo Severini
- Subjects
Male ,Plasmodium vivax ,Case Report ,Drug resistance ,Vivax ,Lactones ,0302 clinical medicine ,MDR ,030212 general & internal medicine ,Artemisinin ,Malaria, Falciparum ,Antimalarials ,Cambodia ,Falciparum ,Genes ,Malaria ,Multiple ,Travel medicine ,Adult ,Artemisinins ,Atovaquone ,Coinfection ,Drug Combinations ,Humans ,Plasmodium falciparum ,Proguanil ,Quinine ,Treatment Outcome ,Drug Resistance, Multiple ,Travel ,Parasitology ,Infectious Diseases ,biology ,medicine.drug ,lcsh:Arctic medicine. Tropical medicine ,lcsh:RC955-962 ,030231 tropical medicine ,lcsh:Infectious and parasitic diseases ,03 medical and health sciences ,parasitic diseases ,medicine ,Malaria, Vivax ,lcsh:RC109-216 ,medicine.disease ,biology.organism_classification ,Virology ,Multiple drug resistance ,Genes, MDR - Abstract
Background Imported cases of multidrug resistant Plasmodium falciparum and treatment failure with artemisinin-based regimens, although rare, have been described also in Western countries and their management is often challenging. This is also due to an inadequate knowledge and implementation of health prevention measures. Case report A complex case of imported malaria caused by Plasmodium vivax/P. falciparum isolates in a patient who was not taking chemoprophylaxis while he was travelling in Cambodia is reported in this article. After failures of artemisinin-based and both oral and intravenous quinine-based regimens, a multidrug resistant P. falciparum was detected. The patient was successfully treated with atovaquone–proguanil. Conclusions This experience highlights the importance of a careful management that should be based not only on the most up-to-date guidelines, but also on the awareness of a rapidly evolving scenario.
- Published
- 2017
11. Comment on: Integrase strand-transfer inhibitor polymorphic and accessory resistance substitutions in patients with acute/recent HIV infection
- Author
-
Claudia Fabrizio, Antonella Lagioia, Grazia Punzi, Luciana Lepore, Gioacchino Angarano, Annalisa Saracino, and Laura Monno
- Subjects
0301 basic medicine ,Pharmacology ,Microbiology (medical) ,Genetics ,030106 microbiology ,Human immunodeficiency virus (HIV) ,Biology ,medicine.disease_cause ,Virology ,03 medical and health sciences ,Integrase strand transfer inhibitor ,0302 clinical medicine ,Infectious Diseases ,medicine ,Pharmacology (medical) ,In patient ,030212 general & internal medicine - Published
- 2017
12. Hepatic encephalopathy in the course of anti-HCV therapy with paritaprevir/ritonavir, ombitasvir, dasabuvir and ribavirin
- Author
-
Francesco Resta, Claudia Fabrizio, Annalisa Saracino, Gioacchino Angarano, and Michele Milella
- Subjects
Microbiology (medical) ,Dasabuvir ,business.industry ,Anti hiv ,Ribavirin ,General Medicine ,medicine.disease ,Virology ,Ombitasvir ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Infectious Diseases ,chemistry ,Paritaprevir ,medicine ,Pharmacology (medical) ,Ritonavir ,030212 general & internal medicine ,business ,Hepatic encephalopathy ,030217 neurology & neurosurgery ,medicine.drug - Published
- 2016
13. DAA-based treatment in HCV and HIV/HCV co-infected patients in real world: data from a large single-centre experience
- Author
-
G. Angarano, Nicoletta Ladisa, Giuseppe Bruno, Laura Monno, Claudia Fabrizio, Michele Milella, Raffaele Dell’Acqua, Eugenio Milano, and Annalisa Saracino
- Subjects
Single centre ,Hepatology ,business.industry ,Medicine ,business ,Virology ,Real world data - Published
- 2017
14. Hepatitis C virus clearance after direct-acting antivirals in cirrhotic patients by stages of liver impairment: the ITAL-C network study
- Author
-
Antonio Metrangolo, Giuseppe Bruno, Pietro Gatti, Salvatore Rizzo, Antonio Massimo Ippolito, Michele Milella, Emanuela Ciracì, Gianfranco Lauletta, Piera Tundo, Luca Fontanella, Teresa Santantonio, C. Masetti, Claudia Fabrizio, Michele Barone, Fabio Conti, P. Andreone, Vincenzo Messina, Angelo Andriulli, M. Zappimbulso, Massimo Fasano, G.B. Gaeta, Giuseppe Cuccorese, Antonio Patrizio Termite, Nicola Napoli, Gianluca Brancaccio, A. Smedile, Raffaele Cozzolongo, Francesco Morisco, Vito Carretta, Maria Rosa Valvano, and Ruggiero Francavilla
- Subjects
03 medical and health sciences ,0302 clinical medicine ,Hepatology ,business.industry ,030220 oncology & carcinogenesis ,Hepatitis C virus ,Medicine ,030211 gastroenterology & hepatology ,business ,DIRECT ACTING ANTIVIRALS ,medicine.disease_cause ,Virology - Published
- 2017
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.